Ultrasound Historical Financial Summary
Diagnostic Agent Portfolio with Industry-wide Compatibility ☑6 GE HealthCare
Contrast Media
Injectable agents used to improve
visualization and diagnostic value of scans
~$5B
Molecular Imaging
Radioactive tracers used in SPECT
& PET procedures
~$5B
Why We Win in PDx
1
Continued innovation across
established product portfolio and
pipeline to improve clinical
Industry-a)
Estimated
Growth-b)
X-Ray/CT
OMNIPAQUE™
(IOHEXOL) INJECTION
Mid-Single Digit %
MR
Clariscan™
(gadoterate meglumine)
injection for intravenous use
VISIPAQUE™ OMNISCAN™
Mid-Single Digit %
Ultrasound
SPECT
OPTISON™
(Perflutren Protein-Type A Microspheres
Injectable Suspension, USP)
(IODIXANOL) INJECTION (GADODIAMIDE) INJECTION SONAZOID
ulrichINJECT
CT motion™
PERFLUOROBUTANE MICROBUBBLES
TM
DaTscan
Ioflupane 1123 Injection
(Neurology)
MYOVIEW™
(Kit for the Preparation of
Technetium Tc99m Tetrofosmin
for Injection)
(Cardiology)
PET
VIZAMYĽ
Flutemetamol F18
Injection (Neurology)
CERianna
effectiveness and efficiency
Scale advantages through
2
sophisticated vertically integrated
supply chain in highly regulated
industry
(FLUOROESTRADIOL F 18 INJECTION
(Oncology)
3
FASTlab
Deep customer relationships and
trust in brand built over many
years
TM
Broad Capabilities with Increasing Focus on Attractive Growth Areas
Source: GE HealthCare estimates
Note: Not all products are available worldwide
(a - For the year 2021; does not include Services or Digital markets
(b For the Period 2022-2025
© 2022, General Electric Company. Proprietary information. All rights reserved.
74View entire presentation